2021
Genomic features of rapid versus late relapse in triple negative breast cancer
Zhang Y, Asad S, Weber Z, Tallman D, Nock W, Wyse M, Bey JF, Dean KL, Adams EJ, Stockard S, Singh J, Winer EP, Lin NU, Jiang YZ, Ma D, Wang P, Shi L, Huang W, Shao ZM, Cherian M, Lustberg MB, Ramaswamy B, Sardesai S, VanDeusen J, Williams N, Wesolowski R, Obeng-Gyasi S, Sizemore GM, Sizemore ST, Verschraegen C, Stover DG. Genomic features of rapid versus late relapse in triple negative breast cancer. BMC Cancer 2021, 21: 568. PMID: 34006255, PMCID: PMC8130400, DOI: 10.1186/s12885-021-08320-7.Peer-Reviewed Original ResearchMeSH KeywordsAdultBiomarkers, TumorChemotherapy, AdjuvantDatasets as TopicDisease-Free SurvivalDNA Copy Number VariationsFemaleFollow-Up StudiesGene Expression ProfilingGene Expression Regulation, NeoplasticHumansLogistic ModelsMastectomyMiddle AgedModels, GeneticMutationNeoadjuvant TherapyNeoplasm Recurrence, LocalPrognosisRisk AssessmentTime FactorsTriple Negative Breast NeoplasmsConceptsLate relapseRapid relapseImmune signaturesBreast cancerAnti-tumor CD8 T cellsBackgroundTriple-negative breast cancerTriple-negative breast cancerCD8 T cellsTumor mutation burdenIndependent validation cohortNegative breast cancerFisher's exact testPearson's chi-squared testChi-squared testLogistic regression modelsLuminal signaturePrimary TNBCTNBC subsetImmune subsetsClinical featuresValidation cohortWhole-genome copy numberPrimary tumorM1 macrophagesT cells
2011
Pneumocystis jiroveci Pneumonia in an Atypical Host
Reinbolt R, Alam S, Layman R, Shapiro C, Lustberg M. Pneumocystis jiroveci Pneumonia in an Atypical Host. Clinical Breast Cancer 2011, 12: 138-141. PMID: 22133356, PMCID: PMC3498486, DOI: 10.1016/j.clbc.2011.10.003.Peer-Reviewed Original ResearchAdrenal Cortex HormonesAntibodies, Monoclonal, HumanizedAnti-Infective AgentsAntineoplastic Combined Chemotherapy ProtocolsBendamustine HydrochlorideBevacizumabBreast NeoplasmsCD4 Lymphocyte CountClinical Trials, Phase I as TopicDexamethasoneErlotinib HydrochlorideFemaleHumansLung NeoplasmsMiddle AgedNeoplasm Recurrence, LocalNitrogen Mustard CompoundsPaclitaxelPneumocystis cariniiPneumonia, PneumocystisQuinazolinesTrimethoprim, Sulfamethoxazole Drug CombinationPhase II Trial of Neoadjuvant Exemestane in Combination With Celecoxib in Postmenopausal Women Who Have Breast Cancer
Lustberg M, Povoski S, Zhao W, Ziegler R, Sugimoto Y, Ruppert A, Lehman A, Shiels D, Mrozek E, Ramaswamy B, Layman R, Brueggemeier R, Shapiro C. Phase II Trial of Neoadjuvant Exemestane in Combination With Celecoxib in Postmenopausal Women Who Have Breast Cancer. Clinical Breast Cancer 2011, 11: 221-227. PMID: 21729671, PMCID: PMC3440773, DOI: 10.1016/j.clbc.2011.03.022.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAndrostadienesAntineoplastic AgentsBreast NeoplasmsCarcinoma, LobularCelecoxibCyclooxygenase 2Cyclooxygenase 2 InhibitorsDrug Therapy, CombinationFemaleFollow-Up StudiesHumansImmunoenzyme TechniquesLymphatic MetastasisMiddle AgedNeoadjuvant TherapyNeoplasm InvasivenessNeoplasm Recurrence, LocalNeoplasm StagingPostmenopausePyrazolesReceptor, ErbB-2Receptors, EstrogenReceptors, ProgesteroneSulfonamidesSurvival RateTreatment OutcomeConceptsPathological complete responsePhase II trialEstrogen receptorKi-67Neoadjuvant exemestaneII trialPostmenopausal womenCOX-2Breast cancerDefinitive breast cancer surgeryCOX-2 inhibitor celecoxibSerious cardiac eventsAnti-tumor responseBreast cancer surgeryAddition of celecoxibCOX-2 expressionMajority of womenStable diseaseCardiac eventsPartial responseComplete responseCancer surgeryCore biopsyAromatase inhibitorsHER-2